Intra-Cellular Therapies (ITCI) stock rose more than 35% premarket after Johnson & Johnson (JNJ) agreed to buy the biopharmaceutical company for $132 a share. Read more: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback